The FDA has approved a label update for an inhaled insulin indicated for adults with type 1 or type 2 diabetes, according to ...
MannKind (Nasdaq:MNKD) announced today that it received FDA approval, updating the prescribing information for Afrezza ...
New Afrezza prescribing information outlines higher starting dose conversions for patients transitioning from mealtime ...
Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic ...
In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to fasting blood glucose levels. A fixed-dose regimen of insulin efsitora alfa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results